Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Three Kennedy Trust for Rheumatology Research (KTRR) Fellows at the Kennedy Institute were recently awarded prestigious funding awards, highlighting the success of the KTRR programme in supporting outstanding investigators launch their independent research career.

The KTRR Senior Research Fellowship programme creates a platform for early stage scientists to launch an independent research career; it has also enabled the Kennedy Institute to recruit bright young investigators from across the globe. 

“The KTRR provided a great opportunity for the Institute to recruit the best and brightest after the move to Oxford.” Says Professor Michael Dustin, Director of Research of the Kennedy Institute. “We are all excited by their progress in establishing their research programs and development as independent scientists.”

The five-year fellowships provide awardees with a generous funding package and strong mentorship, embedded within the institute’s outstanding research environment. 

The first of these fellowships was awarded in 2013 to Dr Tal Arnon, who has subsequently received a Wellcome Trust Investigator award in 2014.

Three more Senior Research Fellowships were awarded in 2016, to Dr Jelena Bezbradica Mirkovic, Dr Anjali Kusumbe, and Dr Audrey Gerard.

Dr Kusumbe received an MRC Career Development Fellowship in 2017 and earlier this year Dr Gerard won a BBSRC New Investigator Grant.

More recently, Dr Jelena Bezbradica Mirkovic won an MRC New Investigator Research Grant to study the biology of FAM26F protein in myeloid cells.

She says: “We are grateful to the Kennedy Trust for their support in establishing our independent research programmes. My group is investigating how innate immune cells, such as macrophages and dendritic cells, integrate tissue-derived inflammatory signals to initiate an appropriate effector response to infection or to sterile injury. The MRC New Investigator Grant is an exciting opportunity to investigate what role a poorly characterized protein, FAM26F, plays in the inflammatory process.”

 

Similar stories

Immunology preprint reviews launched in Nature Reviews Immunology

Kennedy Main Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

Drug may boost vaccine responses in older adults

Kennedy Main

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

Living reviews launched by Oxford and Cardiff in the wake of COVID-19 research

Kennedy Main Research

In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.

Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease

Awards Inflammation biology Kennedy Main

Oxford University has today been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

3D imaging reveals the role of blood vessels in hormone production

Kennedy Main Research

New research from the Kusumbe Group at the Kennedy Institute has shown a direct correlation between age-related decline in capillary and artery numbers and hormone production in the endocrine system.

£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships

Awards Kennedy Main

Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.